They populate our intestines by the billions, without us always knowing what they are doing. But in some patients with coronary heart disease, the bacteria seem to speak a completely different language. This is what recent research conducted in South Korea reveals, which highlights a functional shift in the microbiota in people with cardiovascular disorders. What if these bacteria became the new tools of preventive medicine?
The microbiota at the heart of inflammatory disorders
It all starts with a loss of balance. The team from the Samsung Advanced Institute for Health Sciences and Technology in Seoul analyzed fecal samples from 14 patients with coronary heart disease, compared with those from 28 healthy volunteers. Using a high-definition metagenomic sequencing approach, the researchers identified fifteen bacterial species associated with the disease, not by their absolute presence, but by their specific metabolic functions.
Some of them, known for their beneficial effects in a healthy context, turn into agents of imbalance. This is the case ofAkkermansia muciniphila or Megamonas fumiformiswhich, depending on their strain, can either contribute to the protection of the intestinal mucosa or disrupt the metabolism of lipids and fatty acids. Conversely, protective species like Faecalibacterium prausnitzii Or
Slackia isoflavonic converters disappear almost completely in patients, taking with them their anti-inflammatory functions and their ability to produce short-chain fatty acids.
This discreet replacement of bacterial communities is accompanied by a profound functional upheaval. Amino acid metabolism changes direction. The serine, aspartate and arginine degradation pathways go into overdrive, contributing to an environment conducive to chronic inflammation. All in an apparent unchanged bacterial diversity, proof that the problem is not due to the richness of the microbiota, but to its behavior.
When the intestinal microbiota and cardiovascular diseases overlap
Alterations do not only concern species. These are the metabolic functions which reflect a pathological signature. In the group of patients with coronary heart disease, Korean researchers observed an enrichment of several biological pathways anchored in nitrogen and glucose metabolism. The urea cycle and L-citrulline biosynthesis, involved in the regulation of ammonia and blood pressure, appear overexpressed. Bacteria like Alistipes finegoldii Or Escherichia coli contribute largely to this, promoting potentially deleterious deregulation on the vascular and immune levels.
Another pathway highlighted, type III glycolysis, strongly enriched in patient samples. This preferential activation of glucose metabolism by certain bacteria, including opportunistic members of the Enterobacteriaceae family, could reinforce an already present inflammatory environment. At the same time, usually protective pathways such as the biosynthesis of branched amino acids (BCAA) or that of isoleucine fall sharply, accentuating an overall metabolic deficit.
As for the products resulting from these microbial reactions, the researchers have also identified key metabolites. In patients, inosine (a known coronary vasodilator) accumulates, while other molecules, still poorly understood, such as alpha-muricholate or C18:0e MAG, become rare. According to the authors of the study published in the journal mSystems, these signals could serve as early indicators of cardiovascular imbalance, well before the first symptoms.
Identify the culprits to build precision therapies
What if these bacterial signatures could predict disease? This is one of the big promises of the study. By combining microbial and metabolic profiles, the researchers developed a prediction model based on artificial intelligence. This achieves an accuracy score of 89%, a level rarely observed for non-invasive markers. This model is based in particular on the presence or absence of a few key species such as Faecalibacterium prausnitziias well as on the concentration of inosine, confirming the relevance of an integrated approach.
For Han-Na Kim's team, it now becomes possible to design screening tools based on fecal analysis. Such a method could transform the care pathway by identifying individuals at risk before any detectable coronary artery disease. It also opens the way to targeted interventions, such as the modulation of the microbiota through diet, the administration of specific probiotic strains or the inhibition of pro-inflammatory bacterial pathways. Eurekalert reports that this preventive lever could alone reduce a significant part of the global cardiovascular burden.
Behind these clinical perspectives lies a broader revolution. It is no longer just a question of healing, but of intervening upstream, at the invisible level of microbial interactions. What if, tomorrow, heart health required attentive listening to our intestinal flora?
With an unwavering passion for local news, Christopher leads our editorial team with integrity and dedication. With over 20 years’ experience, he is the backbone of Wouldsayso, ensuring that we stay true to our mission to inform.
